Ipsen S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0MH6.IL | 300558.SZ | 000597.SZ | 4119.TW | IOLCP.NS | 42C.SI | |
|---|---|---|---|---|---|---|
| Market cap | 13.98B | 20.76B | 6.41B | 6.05B | 55.50B | 515.12M |
| P/E (TTM) | 32.3 | 77.9 | 34.5 | 99.2 | 27.3 | — |
| Forward P/E | — | 29.2 | — | 9.0 | 17.5 | 247.4 |
| Price/book | 3.8 | 3.2 | 1.2 | 1.1 | 2.9 | 33.6 |
| Dividend yield | 1.06% | 0.31% | 1.23% | 1.47% | 0.54% | — |
| 1-year change | +24.50% | −12.57% | −20.28% | −9.43% | +102.86% | +259.26% |
| Today | +1.45% | +1.62% | +0.22% | −0.59% | +2.89% | −3.09% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All 0MH6.IL news ›Ipsen places €480m bet on Genfit's liver drug elafibranor
Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis (NASH), but pledged to press on with the drug in other indications – and now has the help of fellow French pharma group…
Gilead, Ipsen build the case for their PBC drugs at EASL
Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term efficacy and safety. Two-year data from the…
FDA clears Ipsen’s primary biliary cholangitis drug
Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC). Iqirvo (elafibranor) is also the first new therapy…
Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight
Oct 02, 2024, 17:31 ET LAS VEGAS, Oct. 2, 2024 /PRNewswire/ -- Primary biliary cholangitis (PBC), previously referred to as primary biliary cirrhosis, is a long-term liver condition characterized by the gradual destruction of the small…
Ipsen: Incorporating solid H1 operational performance + guidance upgrade
Eps change Change in target price € 204 vs 197 +3.25% Although our estimates have increased by double digits, the target price has been raised at a lower rate due to Ipsen's near- and mid-term... Ipsen: Incorporating solid H1 operational…
Ipsen Announces Board and Committee Changes
Published on 09/18/2026 at 04:20 am EDT Ipsen announced the co-optation of Mariette Finet as a Director to its Board of Directors, effective September 18, 2026. Mariette Finet succeeded Michèle Ollier, who resigned from her position as…
Ipsen extends its pullback despite AlphaValue
A day after a 1.06% decline, Ipsen's drop is accelerating despite a positive note from AlphaValue. ... The research firm reaffirmed its add recommendation on the pharmaceutical group's stock and slightly raised its price target to â¬204…
Ipsen S.A. (IPSEY) Q2 2026 Sales/Trading Call Transcript
Ipsen S.A. (IPSEY) Q2 2026 Sales/Trading Call October 22, 2026 7:00 AM EDT David Loew - MD, CEO & DirectorAymeric Le Chatelier - Executive VP & CFOChristelle Huguet - Executive VP and Head of R&D Victor Floch - BNP Paribas, Research…
Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance
PARIS, FRANCE, 22 October 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year-to-date and third quarter of 2026. Full-year 2026 guidance Based on the strong…
Ipsen raises 2026 sales growth outlook to 23% after Q3 sales jump 28%
Ipsen Q3 results: sales up 28.3% to €1.17B, FY2026 guidance raised to ~23% CER and ~39% margin. - Sales of €1.17B, up 28.3% as reported and 26.7% at constant exchange rates (CER). Nine-month sales: €3.36B, up 23% as reported and 24.6% at…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com4
- seekingalpha.com4
- defenseworld.net2
- stocktitan.net2
- pharmaphorum.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.